816 related articles for article (PubMed ID: 12429797)
21. Cell adhesion molecules P-cadherin and CD24 are markers for carcinoma and dysplasia in the biliary tract.
Riener MO; Vogetseder A; Pestalozzi BC; Clavien PA; Probst-Hensch N; Kristiansen G; Jochum W
Hum Pathol; 2010 Nov; 41(11):1558-65. PubMed ID: 20621328
[TBL] [Abstract][Full Text] [Related]
22. Clinicopathologic analysis of combined hepatocellular-cholangiocarcinoma according to the latest WHO classification.
Akiba J; Nakashima O; Hattori S; Tanikawa K; Takenaka M; Nakayama M; Kondo R; Nomura Y; Koura K; Ueda K; Sanada S; Naito Y; Yamaguchi R; Yano H
Am J Surg Pathol; 2013 Apr; 37(4):496-505. PubMed ID: 23388123
[TBL] [Abstract][Full Text] [Related]
23. Sarcomatous cholangiocarcinoma.
Gupta K; Powari M; Dey P
Diagn Cytopathol; 2003 Mar; 28(3):168-9. PubMed ID: 12619101
[No Abstract] [Full Text] [Related]
24. Diagnostic utility of GLUT1 in the differential diagnosis of liver carcinomas.
Roh MS; Jeong JS; Kim YH; Kim MC; Hong SH
Hepatogastroenterology; 2004; 51(59):1315-8. PubMed ID: 15362741
[TBL] [Abstract][Full Text] [Related]
25. Tenascin expression at the invasive front is associated with poor prognosis in intrahepatic cholangiocarcinoma.
Aishima S; Taguchi K; Terashi T; Matsuura S; Shimada M; Tsuneyoshi M
Mod Pathol; 2003 Oct; 16(10):1019-27. PubMed ID: 14559985
[TBL] [Abstract][Full Text] [Related]
26. The diagnostic value of cytokeratins and carcinoembryonic antigen immunostaining in differentiating hepatocellular carcinomas from intrahepatic cholangiocarcinomas.
Stroescu C; Herlea V; Dragnea A; Popescu I
J Gastrointestin Liver Dis; 2006 Mar; 15(1):9-14. PubMed ID: 16680226
[TBL] [Abstract][Full Text] [Related]
27. Primary liver carcinoma arising in people younger than 30 years.
Klein WM; Molmenti EP; Colombani PM; Grover DS; Schwarz KB; Boitnott J; Torbenson MS
Am J Clin Pathol; 2005 Oct; 124(4):512-8. PubMed ID: 16146811
[TBL] [Abstract][Full Text] [Related]
28. Hepatic resection for intrahepatic cholangiocarcinoma: relation to gross tumor morphology.
Itamoto T; Asahara T; Katayama K; Nakahara H; Fukuda T; Yano M; Hino H; Nakahara M; Dohi K; Shimamoto F
Hepatogastroenterology; 2001; 48(40):1129-33. PubMed ID: 11490816
[TBL] [Abstract][Full Text] [Related]
29. Intrahepatic clear cell cholangiocarcinoma: immunohistochemical aspects in a very rare type of cholangiocarcinoma.
Haas S; Gütgemann I; Wolff M; Fischer HP
Am J Surg Pathol; 2007 Jun; 31(6):902-6. PubMed ID: 17527078
[TBL] [Abstract][Full Text] [Related]
30. Diagnostic significance of aquaporin-1 in liver tumors.
Mazal PR; Susani M; Wrba F; Haitel A
Hum Pathol; 2005 Nov; 36(11):1226-31. PubMed ID: 16260277
[TBL] [Abstract][Full Text] [Related]
31. Clinicopathologic features of patients with intrahepatic cholangiocarcinoma who are seropositive for alpha-fetoprotein-L3 and those with combined hepatocellular and cholangiocarcinoma.
Okuda H; Shiratori K; Yamamoto M; Takasaki K; Nakano M
J Gastroenterol Hepatol; 2006 May; 21(5):869-73. PubMed ID: 16704538
[TBL] [Abstract][Full Text] [Related]
32. Assessment of Glut-1 expression in cholangiocarcinoma, benign biliary lesions and hepatocellular carcinoma.
Zimmerman RL; Fogt F; Burke M; Murakata LA
Oncol Rep; 2002; 9(4):689-92. PubMed ID: 12066193
[TBL] [Abstract][Full Text] [Related]
33. Mixed hepatocellular-cholangiocarcinoma may derive from "hepatogones".
Hunt JP; Varnholt H
Hepatobiliary Pancreat Dis Int; 2008 Feb; 7(1):105; author reply 105-6. PubMed ID: 18234649
[No Abstract] [Full Text] [Related]
34. Clinicopathological correlates of aspartyl (asparaginyl) beta-hydroxylase over-expression in cholangiocarcinoma.
Maeda T; Taguchi K; Aishima S; Shimada M; Hintz D; Larusso N; Gores G; Tsuneyoshi M; Sugimachi K; Wands JR; de la Monte SM
Cancer Detect Prev; 2004; 28(5):313-8. PubMed ID: 15542253
[TBL] [Abstract][Full Text] [Related]
35. Intrahepatic cholangiocarcinoma with multicystic, mucinous appearance and oncocytic change.
Fujii T; Harada K; Katayanagi K; Kurumaya H; Nakanuma Y
Pathol Int; 2005 Apr; 55(4):206-9. PubMed ID: 15826247
[TBL] [Abstract][Full Text] [Related]
36. The expression of cytokeratins 7, 19, and 20 in primary and metastatic carcinomas of the liver.
Maeda T; Kajiyama K; Adachi E; Takenaka K; Sugimachi K; Tsuneyoshi M
Mod Pathol; 1996 Sep; 9(9):901-9. PubMed ID: 8878022
[TBL] [Abstract][Full Text] [Related]
37. Intrahepatic cholangiocarcinoma and combined hepatocellular-cholangiocarcinoma: a Western experience.
Portolani N; Baiocchi GL; Coniglio A; Piardi T; Grazioli L; Benetti A; Ferrari Bravo A; Giulini SM
Ann Surg Oncol; 2008 Jul; 15(7):1880-90. PubMed ID: 18443881
[TBL] [Abstract][Full Text] [Related]
38. Combined hepatocellular cholangiocarcinoma: prognostic factors investigated by computed tomography/magnetic resonance imaging.
Lin G; Toh CH; Wu RC; Ko SF; Ng SH; Chou WC; Tseng JH
Int J Clin Pract; 2008 Aug; 62(8):1199-205. PubMed ID: 17537192
[TBL] [Abstract][Full Text] [Related]
39. Decreased intratumoral arteries reflect portal tract destruction and aggressive characteristics in intrahepatic cholangiocarcinoma.
Aishima S; Iguchi T; Nishihara Y; Fujita N; Taguchi K; Taketomi A; Maehara Y; Tsuneyoshi M
Histopathology; 2009 Mar; 54(4):452-61. PubMed ID: 19309397
[TBL] [Abstract][Full Text] [Related]
40. The expression of matrix metalloproteinases in intrahepatic cholangiocarcinoma, hilar (Klatskin tumor), middle and distal extrahepatic cholangiocarcinoma, gallbladder cancer, and ampullary carcinoma: role of matrix metalloproteinases in tumor progression and prognosis.
Kirimlioğlu H; Türkmen I; Başsüllü N; Dirican A; Karadağ N; Kirimlioğlu V
Turk J Gastroenterol; 2009 Mar; 20(1):41-7. PubMed ID: 19330734
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
